Trial
NCT04415151
Tofacitinib for Treatment of Moderate COVID-19
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Yale University
Collaborators
—
Condition
COVID-19 Pneumonia
Intervention
Tofacitinib 10 mg
Why stopped
Study terminated due to lack of enrollment reflecting the decrease in number of COVID infections. There were no safety and/or efficacy concerns involved in the decision to stop enrollment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-28